Perrigo Co. Hits 52-Week Low at USD 20.41 Amid Ongoing Struggles

Perrigo Co. Plc, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 20.41 as of October 31, 2025. This decline marks a significant downturn for the company, which has seen its stock price decrease by 23.92% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
The company's financial metrics reveal a challenging landscape, with a market capitalization of USD 3,072 million and a price-to-book ratio of 0.69. Perrigo's return on equity stands at 0.37%, indicating limited profitability. The company has reported a net profit loss of USD 67.46 million over the past nine months, reflecting a staggering decline of 202.37%. Additionally, the pre-tax profit for the most recent quarter fell by 90.52%, further highlighting the difficulties faced.

With a dividend yield of just 0.04% and a debt-to-equity ratio of 0.72, Perrigo's financial health appears strained. The stock's performance has consistently lagged behind the benchmark S&P 500 over the last three years, underscoring ongoing challenges in the market.